https://www.realclearpolitics.com/articles/2020/04/18/its_time_for_the_white_house_to_focus_on_drug_approvals_142941.html
In this COVID-19 era, it’s the scientists who will ultimately get us back to work. It is time for the Trump administration to acknowledge this and adjust its public communication strategy accordingly. It is hard to envision a scenario looking like the “normal” we all crave until we have therapeutics to protect us from the coronavirus’s effects as we await a vaccine to prevent us from catching it. Once we all know we can take a drug that will minimize symptoms and possibly prevent infection in the first place, we can interact safely in ways that even a ramped-up testing regime will not allow.
Daily White House briefings, and as a result the media and the American public, have been fixated up to now on the response to the pandemic from the administration and Congress. These updates primarily focus on three of the four main categories of activity: federal aid to businesses and displaced workers, needed supplies and equipment for our health care system, and the social distancing regimen complete with handwashing and homemade masks. The two medical faces of this crisis, Drs. Anthony Fauci and Deborah Birx, have concentrated on the last two and keep faithfully explaining what the administration is doing, or should be doing, to increase testing, equip frontline workers, and ultimately flatten the curve.
We hear much less about the fourth category of activity, that is, the race to find a therapeutic solution to combat the virus while we await a vaccine. Therapeutics include anti-viral drugs that inhibit the coronavirus and antibody therapies that boost immunity to the virus, and possibly off-label use of existing drugs.